On June 11, 2020, LHC Group, Inc. (the "Company") announced that its Board of Directors has promoted Joshua Proffitt, the Company's current Executive Vice President, Chief Financial Officer and Treasurer, to the position of President of the Company, and has appointed Robert Williams to serve as its Executive Vice President, Chief Financial Officer and Treasurer, effective July 13, 2020.

        Mr. Williams, age 51, joins the Company from ChenMed where he served as vice president of strategic financial operations since 2017.  Prior to ChenMed, Mr. Williams served as chief financial officer of Altegra Health (part of Change Healthcare) during 2017, vice president of finance with Blue Cross Blue Shield of Michigan from 2015 to 2017, chief financial officer of Active Health Management (a care management and health information technology division of Aetna Inc.) from 2011 to 2015, and several roles at Barclays PLC from 2007 to 2011, including director of business intelligence with Barclays Wealth and chief financial officer with Barclaycard Global Operations and Transformation. Prior to Barclays, he spent 10 years of his career with American Express Company with various financial titles and responsibilities. Mr. Williams has a bachelor's degree with honors in economic history from University of Hull, UK and is a member of Chartered Institute of Management Accountants England & Wales.

        Mr. Williams and the Company entered into an employment agreement effective as of July 13, 2020 (the "Employment Agreement"), pursuant to which he will receive an annual salary of $500,000, subject to annual review by the Compensation Committee of the Board. Mr. Williams will be eligible to earn an annual bonus based on achievement of performance goals established from year to year by the Compensation Committee, and will be eligible for grants of stock awards under the Company's long-term incentive plan. Mr. Williams will receive a one-time grant of restricted stock having a value equal to $250,000, based on the closing price of the Company's common stock on July 13, 2020. The restricted stock vests in equal annual installments over five years, subject to Mr. Williams's continued employment with the Company. 

        Pursuant to the Employment Agreement, in the event Mr. Williams's employment is terminated by the Company without Cause or by Mr. Williams for Good Reason (as such terms are defined in the Employment Agreement), Mr. Williams would receive a prorated annual bonus for the year of termination, and a severance payment equal to 1.5 times (or 2.5 times, in the event Mr. Williams's employment is terminated within two years following a change in control of the Company) the sum of (i) his annual salary in effect as of the termination, and (ii) the greater of the average the annual bonuses he earned for the two fiscal years prior to the termination or his target bonus amount for the year in which the termination occurs. All of Mr. Williams's equity awards would either remain outstanding and continue to vest, provided he complies with applicable non-competition provisions, or, if his termination occurs within two years following a change in control, all of his outstanding equity awards would vest immediately. If Mr. Williams elects to continue participation in the Company's group health plans under COBRA, the Company will pay a portion of such costs for 18 months.

        No family relationships exist between Mr. Williams and any of the Company's directors or other executive officers. There are no arrangements between Mr. Williams and any other person pursuant to which Mr. Williams was selected as an officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Williams has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

(d) Exhibits

The following exhibit is furnished with this Current Report on Form 8-K: